Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RQ 00000010

Drug Profile

RQ 00000010

Alternative Names: CJ-12433; RQ-00000010; RQ-10

Latest Information Update: 28 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer HK inno.N; RaQualia Pharma; Virginia Commonwealth University
  • Class Gastrokinetics; Laxatives
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Gastrointestinal disorders

Highest Development Phases

  • No development reported Constipation; Dyspepsia; Gastrointestinal disorders; Gastroparesis

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in Gastrointestinal-disorders(In volunteers) in United Kingdom (PO)
  • 01 Nov 2022 RQ 00000010 is available for licensing in World as of 01 Nov 2022. https://www.raqualia.com/ (RaQualia Pharma pipeline, November 2022)
  • 28 Oct 2021 Phase I development is still ongoing for Gastrointestinal disorders (including gastroparesis, functional dyspepsia, chronic constipation) (RaQualia Pharma pipeline October 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top